RlapsRisk™ BC

RlapsRisk® BC is an AI diagnostic to help pathologists and oncologists determine the right treatment pathway for early breast cancer patients

Compare

Product Description

Assess the risk of breast cancer relapse with RlapsRisk BC

Our research shows accurate discrimination between high and low risk of relapse*

  • Testing – suitable for adults with primary invasive breast cancer (ER+/HER2-)
  • 78% Cumulative Sensitivity – greater than those obtained by standard clinical scores*
  • Dynamic Specificity – achieves 80% specificity for post-treatment, time-dependent accuracy at 5 years*
  • Digital pathology – intended to work with surgically resected tissue on digitized slides
  • PDF report – delivered as a PDF report with user-friendly design
  • Workflow agnostic – deployment is feasible across IMS systems, or even a shared directory

 

Trained with data from a fruitful partnership with Gustave Roussy

Based on 1800 breast cancer patients (incl. 1480 HER2-/HR+)


Validating product performance

We work closely with medical institutions and pathology lab networks to validate our solutions and ensure their performances are robust across clinics, hospitals, and laboratories.

*Garberis IJ, Gaury V, Drubay D, et al. Blind validation of an AI-based tool for predicting distant relapse from breast cancer HES stained slides. Poster presented at: European Society for Medical Oncology (ESMO); May 9th – 13th 2022; Paris France.

Image AI analysis outperforms clinical scores

RlapsRisk BC achieves 78% sensitivity and 80% specificity for post-treatment, time-dependent accuracy at 5 years, outperforming current clinical scores in practice.*

Cumulative Sensitivity/Dynamic Specificity are natural extensions of sensitivity/specificity to the setting of time-to-event outcomes, such as the metastasis-free interval (MFI), understood as the time to distant relapse occurrence from initial surgery. In use here, as they easily accommodate time-dependent outcome status as well as right-censoring.

Professor Fabrice André on RlapsRisk® BC

The device is currently under development, and not for clinical use. Please contact Owkin for more information. Images shown may represent the range of products, or be for illustration purposes only, and may not be an exact representation of the product.

Manufacturer: Owkin France. RlapsRisk is a trademark of Owkin Inc. European Patent Application No. EP21306284.7 / International Application No. PCT/US2022/043692

Information updated on 17th July 2023

Additional Information

Clinical | Research Suitability

Research

Imaging Modality Supported

Brightfield

User Customizable | Application-Specific Algorithms

Application Specific

Supported Assay Types

HES

IVD | Clinical Applications

Outcome prediction I Breast (RUO)

Research Use Only Applications

Outcome prediction I Breast

On-Premise Deployment

yes

Cloud Deployment

yes

TMA Support

no

File Formats Produced | Supported

.svs, Hamamatsu .ndpi, Philips .iSyntax, TIFF/TIF, .mrxs, .wfml

Additional Notes*

RlapsRisk BC product should be used for research purposes only and not interfere with any treatment decision.

Owkin RlapsRisk™ BC

RlapsRisk™ BC



Clicking on the reviews will open them into a new webpage where you can see a detailed review, including individual scores for ease-of-use, reliability, value-for-money and service and support criteria.



There are no reviews yet.